Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company was founded on April 16, 2015 and is headquartered in Tokyo, Japan.
4893 stock has risen by 3.27% compared to the previous week, the month change is a 16.84% fall, over the last year NOILE-IMMUNE BIOTECH INC has showed a 77.27% decrease.
4893 net income for the last quarter is −279.58 M JPY, while the quarter before that showed −16.88 M JPY of net income which accounts for −1.56 K% change. Track more NOILE-IMMUNE BIOTECH INC financial stats to get the full picture.
Today NOILE-IMMUNE BIOTECH INC has the market capitalization of 7.01 B, it has decreased by 11.86% over the last week.
No, 4893 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 4893 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOILE-IMMUNE BIOTECH INC stock right from TradingView charts — choose your broker and connect to your account.
4893 reached its all-time high on Jun 28, 2023 with the price of 775 JPY, and its all-time low was 150 JPY and was reached on Apr 19, 2024. See other stocks reaching their highest and lowest prices.
As of May 1, 2024, the company has 28.00 employees. See our rating of the largest employees — is NOILE-IMMUNE BIOTECH INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOILE-IMMUNE BIOTECH INC technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOILE-IMMUNE BIOTECH INC stock shows the buy signal. See more of NOILE-IMMUNE BIOTECH INC technicals for a more comprehensive analysis. If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOILE-IMMUNE BIOTECH INC EBITDA is −775.39 M JPY, and current EBITDA margin is −244.74%. See more stats in NOILE-IMMUNE BIOTECH INC financial statements.